Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Sovaldi And GILD 2Q $4.1B Possible, $3.5B Minimum

|Includes:Gilead Sciences, Inc. (GILD)

Updated Sovaldi Model shows $4.1B in Sales, translating into $6.5Bnet prouct REVS, and $1.975 in earnings. $3.5B in Sovaldi sales appears to be the minimum possible, IMS data show $2.9B, but only captured 0.88 of sales last qtr, adjusting for that factor, plus ex-US sales, inventory build, and V.A. adding Sovaldi in April to formulary, additional access to Sovaldi from new state Medicaid programs, and correctional systems, we calculate $4.1B for our model.

Disclosure: The author is long GILD.

Stocks: GILD